| Date | Time | Source | Headline | Symbol | Company |
| 12/12/2022 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161 | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 12/05/2022 | 7:15AM | Dow Jones News | IDEAYA Biosciences Gets FDA OK to Fast-Track Melanoma Treatment | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 12/05/2022 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/29/2022 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022 | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/28/2022 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/08/2022 | 6:05AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/08/2022 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/01/2022 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/18/2022 | 6:00AM | PR Newswire (US) | IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/19/2022 | 4:01PM | PR Newswire (US) | IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/15/2022 | 5:04PM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/14/2022 | 10:41PM | PR Newswire (US) | IDEAYA Announces Pricing of Public Offering of Common Stock | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/14/2022 | 5:02PM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/14/2022 | 4:46PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/14/2022 | 4:39PM | PR Newswire (US) | IDEAYA Announces Proposed Public Offering of Common Stock | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/13/2022 | 11:47PM | TipRanks | Robert W. Baird Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/11/2022 | 5:00PM | PR Newswire (US) | IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/06/2022 | 6:00AM | PR Newswire (US) | IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/04/2022 | 11:08AM | TipRanks | ‘The Market Bottom Is Near,’ Says Oppenheimer — Here Are 2 Stocks to Play That Bullish Sentiment | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 08/30/2022 | 9:42AM | PR Newswire (US) | IDEAYA Biosciences to Participate in Investor Conferences in September 2022 | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 08/29/2022 | 6:00AM | PR Newswire (US) | IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 08/25/2022 | 8:25AM | TipRanks | J.P. Morgan Remains a Buy on IDEAYA Biosciences (IDYA) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 08/16/2022 | 8:35AM | TipRanks | Oppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 08/15/2022 | 6:41AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 08/15/2022 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 07/29/2022 | 12:31AM | TipRanks | Robert W. Baird Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 07/27/2022 | 6:14AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 07/27/2022 | 6:05AM | PR Newswire (US) | IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 07/27/2022 | 6:00AM | PR Newswire (US) | IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 06/28/2022 | 6:00AM | PR Newswire (US) | IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK | NASDAQ:IDYA | IDEAYA Biosciences Inc |